Brief: Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation
27/03/2025 12:22
March 27 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O: RIGEL ANNOUNCES SETTLEMENT AGREEMENT RESOLVING TAVALISSE® (FOSTAMATINIB DISODIUM HEXAHYDRATE) PATENT LITIGATION RIGEL PHARMACEUTICALS INC - UNDER SETTLEMENT, ANNORA TO SELL GENERIC TAVALISSE IN Q2 2032 OR EARLIER RIGEL PHARMACEUTICALS INC - CO AND ANNORA TERMINATE ALL ONGOING LITIGATION REGARDING TAVALISSE PATENTS Source text: ID:nPn7Fq2Y5a Further company coverage: RIGL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)